Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR201 in B-cell Malignancies and Autoimmune Diseases
NCT06567080Phase 1Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of jwcar201 in diffuse large B-cell lymphoma (DLBCL) and systemic lupus erythematosus (SLE), sponsored by Renji Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events and Serious Adverse Events at 2 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
jwcar201
03
Conditions
diffuse large B-cell lymphoma (DLBCL)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06567080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567080.